- Home
- » Tags
- » Pomalidomide
Top View
- POMALYST Safely Capsules: 1 Mg, 2 Mg, 3 Mg, and 4 Mg (3) and Effectively
- In Silico Analysis of Enantioselective Binding of Immunomodulatory Imide Drugs to Cereblon Takahiro Murai1, Norihito Kawashita1,2, Yu‑Shi Tian3 and Tatsuya Takagi1,2*
- Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Pomalyst® (Pomalidomide) Capsules
- Profile of Pomalidomide and Its Potential in the Treatment of Myelofibrosis
- Pomalyst® (Pomalidomide)
- Annual Rheumatology & Therapeutics Review for Organizations & Societies
- LCA Oral SACT Counselling Handbook
- Celgene Fact Sheet
- Immunomodulation by Durvalumab and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma Mary H
- RUNX Proteins Desensitize Multiple Myeloma to Lenalidomide Via Protecting Ikzfs from Degradation
- Isatuximab with Pomalidomide and Dexamethasone for Treating Relapsed Or Refractory Multiple Myeloma
- Apremilast Is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity, Cellular Signalling (2014), 2 P.H
- Bristol-Myers Squibb Company
- Assessment Report for Otezla
- Pomalidomide for Cgvhd CC Protocol #: 12-C-0197 J NCT #: NCT01688466 Version Date: 9/14/2018
- Use of Pembrolizumab with Or Without Pomalidomide in HIV-Associated Non-Hodgkin's Lymphoma
- Self-Administered Specialty Drug List
- Pomalidomide Is Nonteratogenic in Chicken and Zebrafish Embryos And
- Dimethyl Fumarate Increases Fetal Hemoglobin, Provides Heme Detoxification, and Corrects Anemia in Sickle Cell Disease
- POMALYST® (Pomalidomide) for Previously Treated Multiple Myeloma
- 206088Orig1s000
- Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
- Caroline Besley September 2016
- Iberdomide (CC-220) Is a Potent Cereblon E3 Ligase Modulator With
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Imids Induce FAM83F Degradation Via an Interaction with Ck1α to Attenuate Wnt Signalling
- Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Refractory and Proteasome Inhibitor-Exposed Myeloma
- A Phase 1 Study of Ruxolitinib, Lenalidomide and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
- Caresource Prior Authorization Criteria (Updated November, 2019)
- 1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
- POMALYST (Pomalidomide) Capsules, for Oral Use Pembrolizumab Was Added to Dexamethasone and a Thalidomide Initial U.S
- Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts
- Mandatory Specialty Drug List
- Pomalyst (Pomalidomide) Annual Review Date: 09/17/2020
- Pomalidomide > Printer-Friendly PDF
- Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
- POMALYST Product Monograph
- Guidelines for ATC Classification and DDD Assignment 2021
- A Novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in Imid- Resistant Multiple Myeloma (MM) Xenograft Models
- Thalidomide and Its Analogs: a Potential Immunomodulatory Alternative for Treating Liver Diseases and Cirrhosis
- Suffixes Used in the Selection of INN and Their Published INN May 2018
- Product Information for Auspar Pomalidomide Pomalyst Celgene Australia Pty Ltd PM-2013-02037-1-4 Final 13 October 2014
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Haematology Clinical Guidelines (Lancashire & South Cumbria)
- Paragraph IV Patent Certifications (PPIV)
- Pomalidomide (Pomalyst®)
- Pomalidomide and Low Dose Dexamethasone
- The Dark Side of Immunotherapy
- Pomalyst® (Pomalidomide)
- Imnovid, INN-Pomalidomide
- Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
- Primary Central Nervous System Lymphoma: a Narrative Review of Ongoing Clinical Trials and Goals for Future Studies
- Pomalyst (Pomalidomide)
- PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
- Access Plans High Risk Prescription List
- An Update on Targeted Therapies in Systemic Sclerosis Based on a Systematic Review from the Last 3 Years Corrado Campochiaro1 and Yannick Allanore2*
- Pomalyst Capsules 1 Mg, Pomalyst Capsules 2 Mg, Pomalyst Capsules 3 Mg, Pomalyst Capsules 4 Mg [Non-Proprietary Name] Pomalidomide (JAN*) [Applicant] Celgene K.K
- Pomalidomide, Dexamethasone, and Daratumumab in Relapsed Refractory Multiple Myeloma After Lenalidomide Treatment
- Pomalidomide
- Molecular Mechanisms of the Teratogenic Effects of Thalidomide
- Pomalyst® (Pomalidomide)
- Thalidomide-Analogue Biology: Immunological, Molecular and Epigenetic Targets in Cancer Therapy
- Pomalidomide Celgene, Through the Centralised Procedure Falling Within the Article 3(1) and Point 4 of Annex of Regulation (EC) No 726/2004
- Pharmacokinetic and Pharmacodynamic Studies Of
- NCT Number: NCT02576977 12-Apr-2018
- Immunology Frontier Research Center